Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1985;7(4):418-23.

Possible involvement of epinephrine in the cardiovascular effect of naloxone in humans

  • PMID: 4016825
Clinical Trial

Possible involvement of epinephrine in the cardiovascular effect of naloxone in humans

J Hernandez et al. Clin Ther. 1985.

Abstract

The opioid-receptor antagonist naloxone was administered intravenously in a 0.8-mg bolus to five healthy volunteers, aged 21 to 31, in a double-blind study designed to investigate the effect of endogenous opioids on blood pressure, heart rate, and urinary excretion of catecholamines in healthy adults. Three hours after administration of naloxone there were significant increases in systolic blood pressure (P less than 0.001) and heart rate (P less than 0.05). The amount of epinephrine excreted in urine during the four hours after administration of naloxone or placebo was significantly higher (P less than 0.05) in subjects given naloxone. These effects support the hypothesis that an endogenous opioid system is involved in the regulation of systolic blood pressure and heart rate in healthy adults. The results also indicate that adrenally released epinephrine could mediate the cardiovascular effect of endogenous opioids.

PubMed Disclaimer

Publication types